Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02653755 · ClinicalTrials.gov registry record · Phase 2
The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer
A Phase 2 study of Breast Cancer Radiation, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 671
- Enrollment target
- 6
- Study locations
NCT02653755: Active Phase 2 study of Breast Cancer Radiation, sponsored by Dana-Farber Cancer Institute.
NCT02653755 is a Phase 2 study of Breast Cancer Radiation that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 671 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (405% higher). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02653755, a Phase 2 study of Breast Cancer Radiation, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 671 participants
- Enrollment target
- 6
- Study locations
Study Summary
This research study is a way of gaining new knowledge about whether patients can omit radiation treatment after undergoing a lumpectomy, also known as "breast conserving surgery". In this trial, we are attempting to identify which patients may not need radiation.
Primary Outcome
Using information gathered from follow-up physical examinations and mammography, the 5-year risk of local regional recurrence in women who omit radiotherapy post-lumpectomy will be evaluated.
Conditions Studied
Interventions
- DEVICE Prosigna
Study Locations (6)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
New York
- NYU Langone Health - New York
- Memorial Sloane Kettering Cancer Center - New York
Maryland
- Johns Hopkins - Baltimore
Rhode Island
- Lifespan Cancer Institute - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 671 participants |
| Start Date | 2016-05 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
What the registry record for NCT02653755 still lists
NCT02653755 is an interventional study that assigns participants to a tested intervention. The registered 671 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (405% higher).
The record links to 1 condition, with Breast Cancer Radiation appearing as the primary indexed condition, and to 1 intervention - of which Prosigna is the first listed.
NCT02653755 lists 6 locations in 4 states (Massachusetts, New York, Maryland).
Frequently Asked Questions
What is clinical trial NCT02653755 about?
NCT02653755 is a clinical study titled "The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer". This research study is a way of gaining new knowledge about whether patients can omit radiation treatment after undergoing a lumpectomy, also known as "breast conserving surgery". In this trial, we are attempting to identify which patients may not need radiation.
What is the current status of trial NCT02653755?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 671 participants. The study started on 2016-05. Estimated completion is 2026-05.
What conditions does trial NCT02653755 study?
This clinical trial studies the following conditions: Breast Cancer Radiation.
What interventions are being tested in trial NCT02653755?
The interventions under investigation include: Prosigna (DEVICE).
Who is sponsoring clinical trial NCT02653755?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02653755 being conducted?
This trial has 6 study locations across Maryland, Massachusetts, New York, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02653755's enrollment target sits among peer trials
671 48th of 2000 higher than 1,953 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07184944 · 671 participants · Phase 3
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- NCT07185009 · 671 participants · Phase 3
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- NCT05452031 · 672 participants · NA
A Dyadic Sleep Health Approach for Persons With Alzheimer's Disease and Caregivers
- NCT05493254 · 672 participants · NA
Enhancing Smoking Cessation Via Telehealth Options in Primary Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia